M&A Advisor for Medical Spa Owners: 2026 Sell-Side Guide

By Christoph Totter, CT Acquisitions Managing Partner. Last reviewed: July 2026.

An M&A advisor for a medical spa owner in 2026 would run a sell-side process built around three vertical-specific realities: Corporate Practice of Medicine (CPOM) restrictions that dictate deal structure in 30-plus states per the American Bar Association Health Law Section, aesthetic services revenue that private equity has aggressively rolled up since 2019 per the Skytale Group medspa industry updates, and adjusted EBITDA multiples that would range from roughly 6x to 13x depending on scale, membership mix, and MSO structure per Provident Healthcare Partners and Skytale Group. This guide walks through how a qualified medical spa M&A advisor would build the process, what the multiples look like by size band, which buyers are transacting, and how to select a firm.

Executive summary

Medical spa businesses with $1M to $5M of adjusted EBITDA would have transacted at approximately 6x to 9x adjusted EBITDA in 2024 through Q2 2026 per Skytale Group and Provident Healthcare Partners industry updates. Multi-location platforms with above 40% recurring membership revenue, defensible MSO structure, and $8M-plus EBITDA would band at approximately 10x to 13x per the same sources. CPOM restrictions require friendly PC / MSO structure in 30-plus states.

• Medical spa businesses with $1M to $5M of adjusted EBITDA would have transacted at approximately 6x to 9x adjusted EBITDA in 2024 through Q2 2026 per Skytale Group and Provident Healthcare Partners industry updates.
• Multi-location platforms with above 40% recurring membership revenue, defensible MSO structure, and $8M-plus EBITDA would band at approximately 10x to 13x per the same sources.
• CPOM restrictions require friendly PC / MSO structure in 30-plus states per the ABA Health Law analysis, which is the single largest determinant of deal structure and reps and warranties negotiation.
• TA Associates invested in Milan Laser Hair Removal in December 2021 per TA Associates press, marking one of the largest disclosed medspa platform transactions.
• Bain Capital Private Equity owns LaserAway per Bain Capital press, and TSG Consumer Partners owns SkinSpirit per TSG press.
• Lower-middle-market (LMM) medspa sell-side mandates would typically run 6 to 9 months from CIM launch to close per practitioner guidance from International Business Advisors and consistent with the timelines in the Axial 2025 Lower Middle Market Review.
• Working capital pegs, R&W insurance uptake, and Q of E rigor at LMM medspa scale materially affect net proceeds per Marsh M&A insurance data and BDO transaction advisory guidance.

Key findings

Medspa adjusted EBITDA multiples for $1M-$5M sellers would sit in the 6x to 9x band, per Skytale Group quarterly medspa reports. Multi-site platforms with MSO structure and durable membership revenue above 40% would command 10x to 13x, per Provident Healthcare Partners and Skytale. CPOM friendly-PC structuring is required in a majority of US states per the ABA Health Law Section , and the state medical board rules govern non-physician injector.

1. Medspa adjusted EBITDA multiples for $1M-$5M sellers would sit in the 6x to 9x band, per Skytale Group quarterly medspa reports.
2. Multi-site platforms with MSO structure and durable membership revenue above 40% would command 10x to 13x, per Provident Healthcare Partners and Skytale.
3. CPOM friendly-PC structuring is required in a majority of US states per the ABA Health Law Section, and the state medical board rules govern non-physician injector supervision (NP, PA, RN scope) per state boards including the Medical Board of California and Texas Medical Board.
4. Botox off-label use, HIPAA on before-and-after photo consent, and REMS device compliance are standard due diligence workstreams per FDA guidance and the HHS HIPAA rules.
5. Advisor fees for LMM medspa mandates would typically follow a modest monthly retainer plus a success fee scaled to enterprise value, aligned with the Axial LMM data and consistent with CT Acquisitions’ 2026 M&A advisor fees breakdown.
6. Named PE-backed platforms actively rolling up the vertical include Bain Capital’s LaserAway, TA Associates’ Milan Laser, TSG Consumer’s SkinSpirit, L Catterton’s Ideal Image, and Harvest Partners’ Advanced Dermatology and Cosmetic Surgery medspa arm.
7. The recognized boutique medspa M&A advisor is Skytale Group, which publishes the industry’s most cited quarterly comps report.
8. Provident Healthcare Partners covers larger medspa platform transactions and adjacent aesthetic services roll-ups.
9. Sun Acquisitions covers sub-$3M EBITDA medspa mandates per Sun Acquisitions industry page, and specialty M&A firms active in this space also include The DAK Group.
10. CT Acquisitions positions as another lower-middle-market option for medspa owners, owner-aligned on fees, per /m-and-a-advisory/.

What M&A multiples do medical spas sell for by size band?

Adjusted EBITDA multiples for medspa sellers in 2024 through Q2 2026 would band by scale, membership-revenue mix, and MSO defensibility. The ranges below are drawn from Skytale Group quarterly medspa updates and Provident Healthcare Partners published industry commentary. Blending revenue multiples with SDE ranges would be a category error, and this report keeps them separate. Seller profile Adjusted EBITDA Multiple band (2024 to Q2 2026) Buyer type Single-location owner-operator Under.

Adjusted EBITDA multiples for medspa sellers in 2024 through Q2 2026 would band by scale, membership-revenue mix, and MSO defensibility. The ranges below are drawn from Skytale Group quarterly medspa updates and Provident Healthcare Partners published industry commentary. Blending revenue multiples with SDE ranges would be a category error, and this report keeps them separate.

Seller profile	Adjusted EBITDA	Multiple band (2024 to Q2 2026)	Buyer type
Single-location owner-operator	Under $500K SDE	Small-business comps, typically 2.5x to 4x SDE	Individual buyer, small holdco, ETA / search fund per Stanford Search Fund Study
Established single-site with strong recurring revenue	$500K to $1M SDE / low EBITDA	Approximately 3.5x to 5.5x SDE	Individual, family office, small strategic
Established $1M-$3M EBITDA operator	$1M to $3M EBITDA	Approximately 6x to 8x adjusted EBITDA per Skytale	Small PE, sponsored strategic add-on
Multi-location LMM operator	$3M to $8M EBITDA	Approximately 7x to 10x adjusted EBITDA per Provident	Middle-market PE, sponsored platform add-on
Platform with membership durability and MSO scale	$8M-plus EBITDA	Approximately 10x to 13x per Skytale	Growth equity, upper-middle-market PE

These bands would move with membership mix, injector retention, MSO robustness, and geographic diversification. A single-location seller in a CPOM-strict state without a friendly-PC structure in place would likely trade at the lower end of its band and see structure negotiated during diligence.

What moves the multiple: 12 ranked drivers

The following 12 drivers would materially move the medspa multiple within its band. Rankings reflect how buyers weight each factor in the LMM medspa segment per Skytale Group , Provident Healthcare Partners , and general M&A benchmarks from PitchBook . Recurring membership revenue percentage. Buyers pay a premium for membership programs above 30% to 40% of revenue because they convert a discretionary aesthetic business into a subscription-adjacent model. MSO /.

The following 12 drivers would materially move the medspa multiple within its band. Rankings reflect how buyers weight each factor in the LMM medspa segment per Skytale Group, Provident Healthcare Partners, and general M&A benchmarks from PitchBook.

1. Recurring membership revenue percentage. Buyers pay a premium for membership programs above 30% to 40% of revenue because they convert a discretionary aesthetic business into a subscription-adjacent model.
2. MSO / friendly-PC structure already in place. A defensible structure documented per the ABA Health Law standard is table stakes for institutional buyers.
3. Injector retention and productivity. Non-physician injector economics per Medical Board of California and state-level rules dictate labor gross margin.
4. Site-level EBITDA margin. Buyers benchmark against Skytale median site-level margins, and consistent above-market margins support a premium.
5. Same-clinic growth trend for 24 to 36 months. Same-site organic growth would be the single strongest quality-of-earnings signal per BDO transaction advisory guidance.
6. Product concentration risk. Reliance on any single manufacturer (for example, Botox from Allergan Aesthetics, an AbbVie business per AbbVie IR) would flag concentration risk.
7. State CPOM regime. Sellers in CPOM-strict states (CA, TX, NY, and similar) would face harder buyer diligence and stricter reps per the ABA Health Law Section.
8. Lease terms and remaining option years. Consumer-facing sites need lease durability and buyers underwrite renewal risk.
9. Owner add-back defensibility. Sellers should expect a rigorous quality-of-earnings review, as summarized in the CT deep-dive at /quality-of-earnings-report-seller-deep-dive/.
10. Marketing spend efficiency (CAC and repeat rate). Buyers scrutinize digital spend, Meta and Google mix, and repeat visit ratios.
11. Clinical mix. A book weighted toward injectables and energy-based device services generally supports higher multiples than a book weighted toward one-off aesthetics.
12. Data-security and HIPAA program maturity. HIPAA breach exposure and before-and-after photo consent processes per HHS would surface in diligence.

Which PE-backed platforms are rolling up the medspa vertical?

Institutional consolidation of the medspa vertical accelerated after 2019 and continued through 2024 to Q2 2026 per Skytale Group reports. The named PE-backed platforms below are all verifiable via sponsor and portfolio company press. LaserAway , backed by Bain Capital Private Equity . Nationwide laser and aesthetics platform. Milan Laser Hair Removal , backed by TA Associates since December 2021. Category-leading laser hair removal platform. SkinSpirit , backed by TSG.

Institutional consolidation of the medspa vertical accelerated after 2019 and continued through 2024 to Q2 2026 per Skytale Group reports. The named PE-backed platforms below are all verifiable via sponsor and portfolio company press.

1. LaserAway, backed by Bain Capital Private Equity. Nationwide laser and aesthetics platform.
2. Milan Laser Hair Removal, backed by TA Associates since December 2021. Category-leading laser hair removal platform.
3. SkinSpirit, backed by TSG Consumer Partners. Multi-site injectable and skin platform.
4. Ideal Image, backed by L Catterton with post-2018 transactions.
5. Advanced Dermatology and Cosmetic Surgery (ADCS) medspa arm, backed by Harvest Partners. Combines dermatology and aesthetic services.
6. Skin Laundry, backed by Wonder Ventures and other private investors per SkinLaundry.com.
7. SEV Laser, a growing platform in laser hair removal per SevLaser.com.

Strategic buyers include large dermatology and aesthetics platforms with medspa arms, plus device manufacturers with aesthetic exposure such as AbbVie (Allergan Aesthetics) and Evolus (NASDAQ: EOLS), whose activity supplies category context. Family office capital increasingly participates in medspa transactions, as covered in the CT overview at /family-office-vs-pe-buyer/.

Who are the recognized boutique M&A advisors specializing in medspa?

Three named firms are recognized as vertical specialists in medspa M&A. Each is described neutrally, with the firm’s own site cited so readers can verify positioning.

Three named firms are recognized as vertical specialists in medspa M&A. Each is described neutrally, with the firm’s own site cited so readers can verify positioning.

Skytale Group

Skytale Group is the recognized boutique advisor for medspa M&A and consulting. Skytale publishes a widely cited quarterly industry report covering multiples, deal count, and buyer activity per Skytale insights. Their focus is medspa, aesthetics, and adjacent consumer-healthcare services.

Provident Healthcare Partners

Provident Healthcare Partners is a healthcare-focused M&A firm that covers larger medspa platform transactions and adjacent aesthetics, dermatology, and physician-services roll-ups. Provident publishes healthcare industry updates on its insights page.

Sun Acquisitions and other specialty firms

Sun Acquisitions runs medspa sell-side mandates in the sub-$3M EBITDA band. Additional specialty M&A firms active in this space include The DAK Group, which covers healthcare and consumer-services LMM mandates.

How is CT positioned to acquire medical spa owners?

CT Acquisitions is another lower-middle-market option for medspa owners in the roughly $1M to $50M enterprise-value range, positioned as owner-aligned on fees and process. CT does not claim vertical dominance in medspa. The recognized specialists are named above and any owner should benchmark advisors. CT’s differentiation is a small institutional-buyer network, a full sell-side or buy-side engagement described at /m-and-a-advisory/ , and fee structures described in the 2026 M&A advisor.

CT Acquisitions is another lower-middle-market option for medspa owners in the roughly $1M to $50M enterprise-value range, positioned as owner-aligned on fees and process. CT does not claim vertical dominance in medspa. The recognized specialists are named above and any owner should benchmark advisors. CT’s differentiation is a small institutional-buyer network, a full sell-side or buy-side engagement described at /m-and-a-advisory/, and fee structures described in the 2026 M&A advisor fees guide. Owners weighing a smaller sub-$3M mandate should also compare with the sister page at /ma-advisor-for-dental-practice/ for how healthcare-adjacent LMM mandates would be structured similarly.

How the medspa sell-side process works, month by month

A typical LMM medspa sell-side mandate would run 6 to 9 months from engagement to close, consistent with the LMM timelines documented in the Axial 2025 LMM Review and the CT playbook at /investment-banking-process-for-selling-a-company/ . Month 1: Engagement and readiness. The advisor scopes financials, tests add-back defensibility, and confirms CPOM structure. The seller assembles data-room materials per the due-diligence checklist . Month 2: Sell-side quality of earnings. A Q of.

A typical LMM medspa sell-side mandate would run 6 to 9 months from engagement to close, consistent with the LMM timelines documented in the Axial 2025 LMM Review and the CT playbook at /investment-banking-process-for-selling-a-company/.

1. Month 1: Engagement and readiness. The advisor scopes financials, tests add-back defensibility, and confirms CPOM structure. The seller assembles data-room materials per the due-diligence checklist.
2. Month 2: Sell-side quality of earnings. A Q of E firm normalizes revenue by service line, membership mix, and site. Sellers can review the process in the CT deep-dive at /quality-of-earnings-report-seller-deep-dive/.
3. Month 3: CIM and buyer list. The advisor builds the confidential information memorandum and a curated buyer list. Institutional buyers include the named PE-backed platforms and sponsored strategics above.
4. Month 4: Outreach and management meetings. Buyers execute NDAs, receive the CIM, and submit indications of interest.
5. Month 5: LOI selection. The advisor negotiates the letter of intent with the leading bidder. Owners can review a template at /business-sale-letter-of-intent-template-seller/.
6. Month 6 to 8: Buyer diligence. Financial, tax, legal, HIPAA, CPOM, injector, lease, and device-safety diligence. R&W insurance quoting per Marsh if applicable.
7. Month 8 to 9: Definitive agreement and close. Working capital peg, closing statement, escrow, and closing.

What are the regulatory and structural mechanics for 2026 medspa deals?

Corporate Practice of Medicine (CPOM)

CPOM prohibits non-physicians from owning medical practices in a majority of US states per the ABA Health Law Section and detailed American Academy of Family Physicians guidance. In a medspa deal, this drives the use of a management services organization (MSO) contracting with a friendly professional corporation (PC) or professional medical corporation. The MSO owns non-clinical assets and provides administrative services. The PC owns the clinical practice. Any structure that blurs this line would face reps-and-warranties pushback.

Medical director requirement

Botox, filler, and laser services require physician sign-off in most states per state medical board rules such as the Medical Board of California. Deal teams verify the medical director agreement, physician liability coverage, and periodic chart review process during diligence.

Non-physician injector supervision

Nurse practitioner, physician assistant, and registered nurse scope varies by state per the National Council of State Boards of Nursing and state medical board rules. In California, injectable services fall under Medical Board of California scope; in Texas, under the Texas Medical Board; in New York, under the NY State Education Department Office of the Professions. Buyers verify supervision documentation and standardized protocols.

FDA and REMS compliance

Off-label injectable use, adverse event reporting, and device REMS programs are diligence workstreams per FDA FAERS guidance and FDA REMS resources.

HIPAA and before-and-after photo consent

Before-and-after photography used in marketing is Protected Health Information under HHS HIPAA rules. Deal teams verify the consent process, retention policy, and website marketing use.

State cosmetology board overlap

Some medspa services (facials, non-injectable skincare) touch cosmetology board jurisdiction. Sellers with a cross-scope service menu would want to confirm licensure of aestheticians in each site.

Non-competes and physician mobility

The FTC’s proposed nationwide non-compete ban was set aside in Ryan LLC v. FTC, N.D. Tex., August 2024 per the Reuters report. State law governs medical-professional non-competes and would materially affect an owner’s post-close role and any physician medical director’s mobility.

How to choose an M&A advisor for a medical spa: 10-point checklist

Owners weighing multiple advisors should apply the following checklist. Each item aligns with the difference between an M&A advisor and a business broker and reflects the advisor competencies documented at /sell-side-advisory-maximize-your-exit-value/ . Vertical experience in medspa. Verify closed medspa mandates, published research, or named PE relationships. CPOM and MSO fluency. The advisor should describe MSO / friendly-PC mechanics from memory and refer clean healthcare counsel. Buyer list depth. Confirm relationships.

Owners weighing multiple advisors should apply the following checklist. Each item aligns with the difference between an M&A advisor and a business broker and reflects the advisor competencies documented at /sell-side-advisory-maximize-your-exit-value/.

1. Vertical experience in medspa. Verify closed medspa mandates, published research, or named PE relationships.
2. CPOM and MSO fluency. The advisor should describe MSO / friendly-PC mechanics from memory and refer clean healthcare counsel.
3. Buyer list depth. Confirm relationships with the named PE-backed platforms above and with sponsored strategics.
4. Fee alignment. Compare retainer sizing and success-fee scaling with peers using the 2026 advisor fees benchmark and the retainer guide.
5. Q of E discipline. The advisor should recommend a Q of E firm with medspa-adjusted-EBITDA rigor per BDO guidance.
6. Injector diligence knowledge. The advisor should know how buyers analyze injector productivity and retention.
7. Working capital methodology. Understand the peg mechanic before signing the LOI.
8. R&W insurance experience. Understand the availability of R&W at the seller’s transaction size per Marsh M&A insurance guidance.
9. References. Speak with prior medspa or aesthetics-adjacent seller references directly.
10. Cultural fit. Sellers spend 6 to 9 months with their advisor; personal fit matters.

What EBITDA multiples apply by deal size in 2026?

EBITDA multiples for lower middle market businesses vary by size, buyer type, and vertical. The table below shows typical bands for privately-held sellers in 2026 based on GF Data and Axial 2025 benchmarks.

EBITDA size band	Typical multiple	Dominant buyer type
$500K to $1M	3.0x to 4.5x	Individual buyers, ETA, small local PE
$1M to $3M	4.0x to 6.0x	Search funds, small PE, family offices
$3M to $10M	5.5x to 8.0x	Lower middle market PE, strategic tuck-ins
$10M to $25M	7.0x to 10.5x	Middle market PE platforms, strategic acquirers

Frequently asked questions

What multiple would a $2M EBITDA medspa command in 2026?

A single-brand or multi-site medspa at $2M adjusted EBITDA would typically transact at approximately 6x to 8x adjusted EBITDA in 2024 to Q2 2026 per Skytale Group. Recurring membership above 30% to 40% and a defensible MSO structure would push toward the higher end. Weak CPOM structuring would pull toward the lower end.

Do I need an M&A advisor or a business broker?

An LMM medspa above roughly $1M of EBITDA would generally benefit from an M&A advisor rather than a Main Street broker. The distinction is covered in detail at /m-and-a-advisor-vs-business-broker/. Advisors run a curated institutional buyer process; brokers list on marketplace platforms.

How much would advisor fees run for a medspa sale?

LMM medspa mandates would typically include a modest monthly retainer credited against a success fee, with the success fee scaled to enterprise value. Complete benchmarks and range tables are at /m-and-a-advisor-fees-2026/ and /ma-advisor-cost/.

How long does a medspa sell-side process take?

An LMM medspa sell-side would typically take 6 to 9 months from CIM launch to close, consistent with the Axial LMM Review and CT’s sell-side process walk-through.

What is CPOM and why does it matter for my medspa sale?

Corporate Practice of Medicine restricts non-physicians from owning medical practices in a majority of US states per the ABA Health Law Section. Buyers require an MSO / friendly-PC structure to be either in place or executable at closing, and this drives deal structure, working-capital scope, and the reps-and-warranties framework.

Which PE firms are buying medspas?

Actively deploying capital in the vertical are Bain Capital via LaserAway, TA Associates via Milan Laser, TSG Consumer Partners via SkinSpirit, L Catterton via Ideal Image, and Harvest Partners via Advanced Dermatology and Cosmetic Surgery. Numerous sponsored strategics and family offices also participate.

Is a search fund or family office a viable buyer for my medspa?

Yes for smaller sellers. Individual searcher-buyers per the Stanford Search Fund Study would typically pursue single-site sellers with $500K to $1.5M SDE. Family offices increasingly pursue medspa platforms directly per Preqin. CT covers the tradeoffs at /search-fund-buyer-vs-pe-buyer/.

What should a medspa owner do 12 months before selling?

Twelve months out: clean up owner add-backs, formalize MSO / friendly-PC structure with healthcare counsel, document injector protocols, install a compliant HIPAA marketing photo consent process, and build a same-clinic growth track record. This preparation would materially move the multiple within the band per Skytale practitioner commentary.

Methodology and data sources

This guide draws on Skytale Group medspa industry updates ( skytalegroup.com/insights ), Provident Healthcare Partners industry commentary ( providenthp.com/insights ), the American Bar Association Health Law Section ( americanbar.org ), FDA guidance ( fda.gov ), HHS HIPAA rules ( hhs.gov ), state medical board rules including the Medical Board of…

This guide draws on Skytale Group medspa industry updates (skytalegroup.com/insights), Provident Healthcare Partners industry commentary (providenthp.com/insights), the American Bar Association Health Law Section (americanbar.org), FDA guidance (fda.gov), HHS HIPAA rules (hhs.gov), state medical board rules including the Medical Board of California (mbc.ca.gov) and Texas Medical Board (dshs.texas.gov), the National Council of State Boards of Nursing (ncsbn.org), PE sponsor and portfolio company press including Bain Capital (baincapital.com), TA Associates (ta.com), TSG Consumer Partners (tsgconsumer.com), L Catterton (lcatterton.com), Harvest Partners (harvestpartners.com), Marsh M&A insurance data (marsh.com), BDO transaction advisory guidance (bdo.com), PitchBook (pitchbook.com), the Axial LMM Review (axial.net/forum), the Stanford Search Fund Study (gsb.stanford.edu), Preqin (preqin.com), the Reuters report on Ryan LLC v. FTC (reuters.com), and AbbVie IR filings covering Allergan Aesthetics (abbvie.com).

All multiple ranges are stated in conditional tense because private-company transactions are not observable in continuous data. Ranges are drawn from published practitioner reports and disclosed transactions. This report is not an appraisal, not investment advice, not legal advice, not tax advice, not financial advice, and not a prediction. It is a synthesis of published sources produced for educational and reference use by business owners and M&A professionals considering a medical spa transaction. Any owner considering a sale should engage qualified counsel, tax advisors, and an M&A advisor with the applicable licenses (Series 79 or applicable jurisdiction) prior to signing any engagement letter or letter of intent.